Andrew L. Salzman, M.D.

Director of Translational Science (Drug Development/Medicine)

Andrew L. Salzman, M.D., is Director of Translational Science. In addition to 175 journal articles, Dr. Salzman holds numerous patents in the fields of medicine, pharmacology, organic chemistry and medical devices. As a pharmaceutical entrepreneur, Dr. Salzman founded and built Inotek Pharmaceuticals, raised $80 million in venture capital and concluded a $600 million license with Genentech based on a pharmacological inhibitor he invented. Dr. Salzman received his undergraduate degree from at Yale University, followed by a medical degree from Harvard Medical School and fellowships in pediatric critical care, neonatology and infectious disease at the Weizmann Institute of Science, Boston Children’s Hospital, Massachusetts General Hospital, University of Massachusetts and Beth Israel Hospital.